CPT code 88280 covers additional karyotype analyses performed after an initial chromosome analysis with karyotype. This cytogenetic laboratory code matters nationally because karyotyping is a key diagnostic tool for detecting chromosomal abnormalities in prenatal, pediatric, oncologic and reproductive contexts; accurate coding affects clinical documentation, claims adjudication, and consistent national reporting. Primary payers discussed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare.

Readers will find a concise overview of what 88280 represents, common clinical and laboratory settings where the service is delivered, and the policy and billing considerations that influence reimbursement and utilization. The publication provides benchmarks where available, summarizes relevant payer coverage trends and documentation expectations, and situates 88280 within related cytogenetic services to clarify clinical intent and billing pathways. Data not available in the input are noted as such in relevant sections. The goal is to equip laboratory managers, billing professionals, and policy analysts with a clear, national-level reference on CPT code 88280 and where it fits in cytogenetic testing workflows.